Currently there are two phase I DBS trials investigating this approach in ultra-resistant schizophrenia that are recruiting patients. The first trial at Hospital Santa Creu i Sant Pau in Barcelona (Clinicaltrials.gov Identifier: NCT02377505) is targeting electrode placement in either the nucleus accumbens or the subgenual ACC. The participants will be randomized to receive stimulation to either of these neuroanatomical sites with the stimulation remaining on until a full 6 months of stabilization is achieved. Those patients who are responsive will then be crossed-over to stimulation-on or stimulation-off groups for 3 months.